Dr. Machado received his MD from the Universidade Federal do Rio Grande do Sul, Brazil. He completed residency and chief residency in internal medicine at the University of Miami, pulmonary and critical care medicine fellowship at the Cleveland Clinic Foundation and post-doctoral research training at the National Heart Lung and Blood Institute.
Dr. Machado's laboratory focuses on the study of pulmonary hypertension and pulmonary complications of sickle cell disease. His research has contributed to the discovery of pulmonary hypertension as a major risk factor for death in adult patients with sickle cell disease. Using human oligonucleotide microarray platforms, genetics and bioinformatics tools, he currently seeks to develop novel diagnostic, prognostic and therapeutic biomarkers for patients with complex disorders such as pulmonary hypertension. His efforts have led to the identification of novel genetic modifiers and biochemical and molecular biomarkers in sickle cell disease and pulmonary hypertension. His laboratory also utilizes animal models of sickle cell disease and pulmonary hypertension to investigate the role of the pulmonary vascular endothelium in regulating vasomotor tone, permeability, vascular proliferation and apoptosis. By combining these approaches, Dr. Machado seeks to gain novel insights into the pathogenesis and treatment of these complex lung disorders, which would hopefully lead to an improvement in the morbidity and mortality associated with sickle cell disease and pulmonary hypertension.
Dr. Machado’s clinical interests include pulmonary hypertension and pulmonary complications of sickle cell disease.